Nicotinic Acid Starvation Could Boost Cancer Drug Effect
Restricting certain nutrients may help treat tumors expressing the NAPRT gene, according to new research.
Updated on Oct. 21, 2026 in Cancer
Researchers have identified that starving tumors of nicotinic acid can make specific cancer cells vulnerable to existing drug therapies. This mechanism, which targets tumors expressing the NAPRT gene, may eventually offer a new strategy for managing several common cancer types.
Why it matters
Many tumors rely on a specific gene to bypass current treatments, but researchers found that restricting dietary nicotinic acid can strip those defenses away. This finding points toward a potential future where combining nutrition-based strategies with targeted inhibitors improves therapeutic outcomes.
This preclinical study utilized mouse models and cell cultures to demonstrate that removing nicotinic acid from the environment sensitizes NAPRT-expressing tumor cells to the inhibitor FK866. While promising, the findings remain preliminary and require validation in human clinical trials.
The players
NAPRT
An enzyme-coding gene that helps certain tumor cells synthesize NAD+ and survive despite drug inhibition.
FK866
A pharmaceutical compound that functions as an NAMPT inhibitor by blocking essential metabolic pathways in cancer cells.
The details
Cancer cells often require NAD+ to maintain energy and repair DNA. Tumors with the NAPRT gene can produce this essential molecule using nicotinic acid, allowing them to resist drugs known as NAMPT inhibitors. Researchers discovered that by creating a nicotinic acid-free environment or using a specialized inhibitor, they could force these tumor cells into a state where they succumb to treatment. This combination approach effectively promoted necrotic cell death in susceptible cells during laboratory testing.
Timeline
2026: Findings published on NAD+ biosynthesis research.
Health Landscape
This study aligns with the broader field of metabolic-targeting cancer therapies by identifying a specific nutrient dependency in tumor cells. It suggests that future oncology treatments could move toward integrating metabolic control to overcome traditional drug resistance.
While these findings are an important discovery for cancer research, they are currently limited to preclinical studies and do not warrant any changes to your diet or cancer care. Patients interested in how emerging metabolic research might impact their specific diagnosis should consult with their oncology care team.
The takeaway
This research reveals that some tumors rely on specific nutrients to resist modern drug treatments. As these studies progress toward potential human trials, patients should prioritize discussing new, research-backed therapies exclusively with their oncologists to ensure their care plans remain safe and evidence-based.
Further reading
For more on the current science of oncological research, visit our Cancer section.
Source note: This article includes information reported by Nature.
